Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI

Author(s):
Steffen Berweck, MD\(^1,2\); Marcin Bonikowski, MD, PhD\(^3\); Heakyung Kim, MD\(^4\); Michael Althaus, MD, FFPM\(^5\); Birgit Flatau-Baqué\(^5\); Daniela Mueller, PhD\(^6\); Marta Dagmara Banach, MD, PhD\(^7\)

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Neurology® Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes.
Corresponding Author:
Steffen Berweck
sberweck@schoen-klinik.de

Affiliation Information for All Authors: 1. Specialist Center for Paediatric Neurology, Neurorehabilitation and Epileptology, Schoen Klinik, Vogtareuth, Germany; 2. Department of Pediatric Neurology and Developmental Medicine, LMU Center for Children with Medical Complexity - Integrated Social Pediatric Center, Dr. von Hauner Children’s Hospital, Ludwig-Maximilians-University (LMU), Munich, Germany; 3. Mazovian Neuropsychiatry Center LLC, Neuro Rehabilitation Department, Movement Analysis Lab, Zagórze n. Warsaw, Poland; 4. Pediatric Rehabilitation Medicine at the Department of Rehabilitation & Regenerative Medicine of Columbia University Irving Medical Center / New York Presbyterian Hospital, New York, NY, USA; 5. Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany; 6. Kantar Health, Munich, Germany; 7. Department of Neurology of the Jagiellonian University, Krakow, Poland;

Contributions:
Steffen Berweck: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data
Marcin Bonikowski: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Analysis or interpretation of data
Heakyung Kim: Drafting/revision of the manuscript for content, including medical writing for content
Michael Althaus: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data
Birgit Flatau-Baqué: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data
Daniela Mueller: Drafting/revision of the manuscript for content, including medical writing for content
Marta Dagmara Banach: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data
Clinical Trial registration number: NCT02270736

Supplemental: Consort checklist, Manuscript version with tracked changes

Statistical Analysis performed by: The statistical analysis was conducted by Birgit Flatau-Baqué, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany


Acknowledgements: The authors thank the patients and study investigators. The authors also thank the experts who contributed to the regular safety reviews throughout the study, Bernhard Dan (Université libre de Bruxelles, Brussels, Belgium), Antigone Syrigou-Papavasiliou (Pendeli Children's Hospital, Athens, Greece), and Imre Velkey (Borsod County Teaching Hospital, Child Health Center, Miskolc, Hungary).

Study Funding: This study was funded by Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany.

Disclosures: S. Berweck was the coordinating investigator in the SIPEXI study, received consultant fees from Ipsen Pharma, and speaker fees from Ipsen Pharma and Pharm Allergan; M. Bonikowski was an investigator in the SIPEXI study, and an investigator in other Merz, Allergan, Ipsen, and Teva studies, received research support from Ipsen, Allergan, and Merz, and personal fees for consultancy and speaking from Ipsen, Merz and Allergan; H. Kim was a consultant for Merz and Allergan, received
research grants from Ipsen, TEVA, and Allergan, and was a pediatric spasticity advisory member for Allergan and Ipsen, received honoraria from Catalyst Medical Education LLC, AiCME Medical Education and American Academy of Physical Medicine & Rehabilitation (AAPM&R); M. Althaus is an employee of Merz Pharmaceuticals GmbH; B. Flatau-Baqué is an employee of Merz Pharmaceuticals GmbH; D. Mueller is a medical writer employed at Kantar Health, Munich, Germany; M. Banach was an investigator in the SIPEXI study, participated in the advisory board and speaker bureau for Merz, and served as a consultant and speaker for Ipsen, Allergan, Kedrion, and Shire.

Abstract

Background and Objectives

This prospective phase III study (SIPEXI) investigated efficacy and safety of repeated injections of incobotulinumtoxinA (incoBoNT/A) for treatment of chronic sialorrhea (drooling) associated with neurological disorders (e.g., cerebral palsy, traumatic brain injury) and/or intellectual disability in children/adolescents.

Methods

The study enrolled 2-17-year-olds with sialorrhea due to neurological disorders and/or intellectual disability. Patients received body weight-dependent doses of incoBoNT/A (20 U to 75 U). A main period with 1 injection cycle (placebo-controlled, double-blind, 6-17-year-olds) was followed by an open-label extension with up to 3 further cycles. An additional cohort of 2-5-year-olds received active treatment throughout the study. Co-primary endpoints were the change in unstimulated salivary
flow rate (uSFR) from baseline to week 4, and the carers' global impression of change scale (GICS) rating at week 4. Adverse events were recorded.

Results
In the main period, 220 patients aged 6-17 years were randomized and treated (148 patients in incoBoNT/A group, 72 patients in placebo group). 35 patients aged 2-5 years received incoBoNT/A (no placebo). 214 patients aged 6-17 years and 33 patients aged 2-5 years continued treatment in the open-label extension period. For the 6-17-year-olds, a significant difference between incoBoNT/A and placebo was seen in the mean uSFR decrease (difference: -0.06 g/min; \( p = 0.0012 \)) and the carers’ GICS rating (difference: 0.28 points; \( p = 0.032 \)) at week 4, in favor of active treatment. The secondary endpoints consistently supported these results. A sustained benefit was observed during the extension. Incidences of adverse events were comparable between incoBoNT/A and placebo and did not increase notably with repeated injections. The most common adverse events were respiratory infections. Efficacy and safety were also favorable in the uncontrolled cohort of 2-5-year-olds.

Discussion
Both co-primary efficacy endpoints were reached and superiority of incoBoNT/A over placebo was confirmed. IncoBoNT/A (up to 75 U, up to 4 cycles) is an effective and well-tolerated treatment for sialorrhea associated with neurological disorders in children.

Study registrations
Clinicaltrials.gov: NCT02270736

Classification of evidence
This study provides Class I evidence that injection of incobotulinumtoxinA decreases drooling in children aged 6-17 years with neurological disorders.

**Introduction**

Sialorrhea (drooling) is a chronic impairment often seen in children with neurodevelopmental disorders and/or intellectual disability, metabolic, and neurodegenerative diseases. Consequences range from quality-of-life issues to increased morbidity (choking, aspiration, pneumonia).\(^1\text{-}^3\) Non-medicinal treatments include functional therapy and surgery.\(^4\) Drugs commonly used are anticholinergics (e.g., scopolamine, glycopyrrolate) with typical systemic side effects like bladder retention, chest congestion, and constipation; and botulinum toxin injections to salivary glands.\(^3,^5\text{-}^7\)

Botulinum toxin blocks acetylcholine release, inhibiting secretion of saliva. Several trials have demonstrated efficacy and safety of intraglandular botulinum toxin injections for sialorrhea in adults\(^8\text{-}^{14}\) and children.\(^1,^{15\text{-}26}\)

At the time of study planning, the clinical effect of repeated botulinum toxin injections for children had not been tested, optimal doses were undefined, and no studies had fulfilled approval requirements. Most were small, uncontrolled, open-label, or retrospective studies with a single injection cycle, or studies without structured safety monitoring.

IncobotulinumtoxinA (incoBoNT/A; botulinum toxin A free from complexing proteins; Xeomin\(^\text{®}\), Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany) was approved for treatment of sialorrhea in adults in the USA in 2018 and in the EU in 2019.

This pivotal phase III study investigated efficacy and safety of incoBoNT/A (weight-adapted doses of 20 U to 75 U) compared with placebo for the treatment of chronic sialorrhea associated with neurological disorders and/or intellectual disability in
children/adolescents. Results from up to 4 consecutive cycles of ultrasound-guided botulinum toxin injections are reported.

Methods

Study design

SIPEXI (Sialorrhea Pediatric Xeomin Investigation) was a prospective, multicenter, phase III study with a randomized, double-blind, parallel-group, placebo-controlled main period (MP) and an open-label extension (OLEX) period. It was conducted from 2015 to 2019 at 27 sites in 6 EU and non-EU countries. Patients were enrolled between February 2015 and December 2017. For safety reasons, patients were recruited sequentially by age: 10-17-year-olds first, then 6-9-year-olds, then 2-5-year-olds. A review committee evaluated safety 4 weeks after every 30 randomized patients, to detect any issues early. Patients aged 6-17 years were randomized (2:1) to receive incoBoNT/A or placebo during the MP, followed by 16 weeks of observation. The 2-5-year-olds received active treatment only. Placebo treatment was considered unethical for this group by the authors and the authority approving the trial design (European Medicines Agency), because it required risk-bearing analgesia and sedation and because one of the co-primary efficacy parameters (salivary flow) could not be measured in this age group, limiting the value of a placebo control. Only patients with a clinical need for re-injection after the MP, as assessed by their physicians, were eligible for treatment in the OLEX, receiving up to 3 incoBoNT/A treatments, each with 16 weeks of observation. The study lasted 72 weeks. Patients assigned to incoBoNT/A received body weight (BW)-dependent total doses of 20 U to 75 U per session. For patients weighing <30 kg, doses were determined according to a dosing scheme of 5 weight classes, resulting in mean doses between 1.3 U and 2.2 U/kg. Patients weighing ≥30 kg received a fixed dose of 75 U. The
total dose was distributed in a 3:2 ratio among all parotid and submandibular glands (4 injections per session). Patients in the placebo arm received equivalent volumes of placebo solution. All injections were ultrasound-guided. Analgesics and sedatives had to be offered to all patients. Further details of study design and dosing are provided in eMethods available from Dryad (https://doi.org/10.5061/dryad.4tmpg4f9p).

**Study population**

Children and adolescents (2-17 years old) included in the study had a neurological disorder (e.g., cerebral palsy [CP] or traumatic brain injury) and/or intellectual disability associated with chronic sialorrhea for ≥3 months prior to screening. A modified Teacher’s drooling scale (mTDS) score of ≥6 (“severe drooling to the extent that clothing becomes damp occasionally”), rated by the investigator, was required. The main exclusion criteria were sialorrhea not related to neurological disorders and/or intellectual disability; a BW <12 kg; clinically present moderate or severe dysphagia (choking more than once a week), except for patients on parenteral nutrition or nutrition via gastrostomy; pediatric epilepsy not well controlled with antiepileptic drugs; any previous treatment with botulinum toxin for any body region (during the year before screening or within the screening period); and extremely poor dental/oral condition.

**Standard protocol approvals, registrations, and patient consents**

The study was registered in the database of the US National Library of Medicine (clinicaltrials.gov; NCT02270736) and the EU Clinical Trials Register (eudract.ema.europa.eu; number 2013-004532-30), and conducted in accordance with the ethical principles outlined in the Declaration of Helsinki. The protocol, informed consent (IC) forms, and other study-related documents were reviewed and approved by local independent ethics committees and institutional review boards. Written IC was obtained from all patients’ parents in accordance with regional
laws/regulations. All patients were informed to the fullest extent possible about the study, in language and terms they were able to understand. Depending on the extent of the patient’s level of understanding and decision-making capacity, the patient assented to the IC given by the patient’s parent(s). Patients of appropriate intellectual maturity personally signed and dated either a separately designed, age-conform written informed assent form or the written IC if their maturity ensured understanding of the wording.

**Outcome measures**

The co-primary efficacy endpoints were the change in unstimulated salivary flow rate (uSFR) from study baseline to week 4 and the carers’ global impression of change scale (GICS) rating at week 4. Secondary efficacy endpoints were the changes from baseline in uSFR and in GICS ratings at week 8 and 12. The analysis of the co-primary and secondary efficacy endpoints was based on the cohort of 6-17-year-olds and compared incoBoNT/A with placebo. Other efficacy endpoints were changes in uSFR and GICS ratings at later visits, and changes in mTDS ratings and in drooling quotient (DQ; percentage of time a patient drooled) during the MP and OLEX. The uSFR was not determined in 2-5-year-olds because the method was considered inappropriate for this group.

The primary safety endpoint was the occurrence of treatment-emergent adverse events (AEs) overall and per injection cycle. Secondary safety endpoints were the occurrence of treatment-emergent AEs of special interest (AESIs) possibly indicative of toxin spread, serious AEs (SAEs), AEs related to treatment, and AEs leading to discontinuation.

Further details of the outcome assessments are provided in eMethods available from Dryad (https://doi.org/10.5061/dryad.4tmpg4f9p).

**Statistical analysis**

*Sample size determination:*
A total of 219 patients aged 6-17 years were planned to be randomized. Based on a 2:1 randomization, it was estimated that 146 patients in the incoBoNT/A group and 73 patients in the placebo group would provide 95% power to show a statistically significant difference between incoBoNT/A and placebo for the co-primary endpoints (two-sided t-tests, significance level α=0.05). In addition, the sample size allowed ≥100 patients to be treated with incoBoNT/A and observed for 1 year (anticipating a 30% dropout rate over 1 year). Furthermore, 30 patients aged 2-5 years were assumed to be a sufficiently large cohort to generate a safety profile for this age group, which was a regulatory requirement.

**Analysis sets:**
Safety analyses were based on the safety evaluation set (SES) of the MP or OLEX, i.e., the subset of patients who received study medication. Efficacy analyses were based on the full analysis set (FAS; identical to MP SES) for the MP and on the SES for the OLEX. Long-term analyses focused on patients who received active treatment already during the MP.

**Statistical method:**
The confirmatory analysis of the co-primary variables was a mixed model repeated measures (MMRM) analysis (two-sided, significance level alpha=0.05) with comparison of least squares (LS) means between incoBoNT/A and placebo, performed on the FAS, limited to patients aged 6-17 years. If both co-primary efficacy variables showed a statistically significant difference to placebo, the superiority of incoBoNT/A over placebo was considered proven. No α-adjustment for multiple testing was necessary. Sensitivity analyses were performed using analysis of covariance (ANCOVA) models and nonparametric tests. For all efficacy parameters, descriptive statistics were provided. For GICS ratings, response rates (%) were calculated, with response defined as a GICS rating of ≥+1 (at least
“minimally improved”). Changes from baseline refer to study baseline. Safety variables were analyzed descriptively.

Further details of the statistical methods are provided in eMethods available from Dryad (https://doi.org/10.5061/dryad.4tmpg4f9p).

**Data availability**

No individual de-identified patient data are shared. Key elements of the protocol and statistical analysis plan, and the main study results are available in the database of the US National Library of Medicine (NCT02270736) and the EU Clinical Trials Register (EudraCT number 2013-004532-30). After regulatory approval in the USA and/or the EU in the respective indication and publication of the primary manuscript, Merz will share for 5 years data that relate to the results reported in this article with qualified researchers who provide a valid research question. Prerequisite is a data sharing contract and shared data may only be used for non-commercial purposes. Proposals should be submitted to data-sharing@merz.com.

**Results**

**Study population**

Overall, 220 patients aged 6-17 years and 36 patients aged 2-5 years were enrolled. All 6-17-year-olds were randomized and treated in the MP (FAS-MP), with 148 patients aged 6-17 years receiving incoBoNT/A and 72 patients aged 6-17 years receiving placebo. Of the 2-5-year-olds, 1 patient withdrew before treatment start and 35 patients were treated with incoBoNT/A in a separate, open-label arm of the MP. A total of 214 patients aged 6-17 years and 33 patients aged 2-5 years were treated in the OLEX (SES-OLEX). Of these, 189 patients aged 6-17 years and all 33 patients aged 2-5 years completed the OLEX (figure 1).
Patients’ baseline characteristics are summarized in table 1. The mean baseline uSFR values (~0.60 g/min) were within the normal range of saliva production for children.27 The mean mTDS ratings and DQs indicated severe drooling with a notable impact on daily life. The incoBoNT/A and placebo groups (6-17 years) were similar with respect to demographics and baseline characteristics.

**Treatment exposure**

During the MP, the 6-17-year-old patients received a mean (SD) dose of 1.91 (0.25) U/kg, ranging from 1.0 to 2.5 U/kg. All patients were treated according to the pre-defined dosing scheme. Considering the numbers of patients per weight group at baseline, this resulted in a median total dose of 40.0 U for patients below 30 kg, with a median dose of 2.0 U/kg. Patients weighing ≥30 kg received 75 U, with a median dose of 1.9 U/kg. The mean doses of the OLEX were similar to those of the MP. For 2 patients, dose reductions were necessary due to AEs (dry mouth and gastric operation) during the 4th cycle.

In the 2-5 years age group, the mean (SD) dose in the MP was 1.70 (0.19) U/kg, with a range of 1.4 to 2.1 U/kg. Similar doses were administered throughout the OLEX. Approximately 90% of patients received analgesics and/or sedatives in all injection cycles.

**Study outcomes**

**Unstimulated salivary flow rate**

The incoBoNT/A treatment group (age 6-17 years) showed consistently greater decreases in LS-mean uSFR from baseline to all time points of the MP, compared to placebo (table 2). Assessing the change from baseline to week 4 (co-primary analysis), the LS-mean difference between incoBoNT/A and placebo was statistically significant in favor of incoBoNT/A. Secondary analyses (results at week 8 and week 12; table 2) and further sensitivity analyses confirmed these results.
Carers’ global impression of change scale rating during MP

The incoBoNT/A group (age 6-17 years) showed consistently higher mean carers’ GICS ratings at all post-treatment visits of the MP, compared to placebo (figure 2), indicating improvements. Assessing the GICS ratings at week 4 (co-primary analysis), the LS-mean (standard error [SE]) result for the incoBoNT/A group (0.91 [0.075]; 95% CI: [0.76; 1.06]) was notably higher than for the placebo group (0.63 [0.104]; 95% CI: [0.43; 0.84]). The LS-mean [SE] difference between the groups was statistically significant (0.28 [0.127]; 95% CI: [0.02; 0.53]; \( p = 0.032 \)). Secondary analyses (results at week 8 and week 12; figure 2) and further sensitivity analyses confirmed these results.

The analysis of GICS response rates further supported the favorable outcomes. More than 60% of patients in the incoBoNT/A group (range from 70.9% at week 4 to 63.0% at week 16) showed a response of at least +1 point on the GICS, compared to <50% in the placebo group (range from 47.9% at week 8 to 34.3% at week 16).

The analysis of both co-primary efficacy variables showed statistically significant improvements, reflecting superiority of incoBoNT/A over placebo for the management of sialorrhea.

Other efficacy assessments

The carers’ and investigators’ mTDS ratings and the DQs showed consistently and notably better outcomes for incoBoNT/A-treated patients than for the placebo group during the MP. In the incoBoNT/A group, the mTDS rating changes from baseline were in the range of -1.5 to -2.0 points on the 9-point scale (mean post-baseline ratings between 5.7 and 6.1 points). The DQ decreases from baseline were between -11% and -14%. For all parameters, the treatment effect appeared to increase from week 4 to week 8, to remain stable to week 12 and then to show some decrease to week 16.
Long-term efficacy with repeated injections

Repeated treatments with incoBoNT/A showed a prolonged and sustained effect. This was consistently seen in all parameters. Mean uSFR decreases from study baseline to week 4 of each treatment cycle became slightly larger with each cycle (figure 3). Treatment effects were still seen at each week 16 visit, although less pronounced. Mean GICS ratings were consistently positive, showing an increasing effect over time (figure 4). The highest ratings around +2 (“much improved”) were reached in the 4th cycle. Only small differences in uSFR changes and GICS ratings were seen between the respective week 4 and week 16 visits of each cycle, indicating stable improvements.

Consistent improvements compared to baseline were also seen for the mTDS and DQ after repeated injections, with a tendency of gradual increment over time.

Efficacy in 2-5-year-old patients

During the MP, GICS ratings showed notable improvements (mean [SD] changes ranged between +1.1 [0.8] and +1.2 [0.8]), as did the carers’ mTDS results (mean [SD] changes from baseline ranged between -2.0 [1.6] and -2.4 [1.9]). The investigators’ mTDS results were similar. DQ outcomes also showed good changes (%) from baseline (mean [SD] ranged between -16.57 [19.65] and -21.18 [23.32]).

In line with the results for 6-17-year-olds, the OLEX outcomes for 2-5-year-olds indicated a sustained effect of incoBoNT/A with notable improvements over time.

Results were consistent across all parameters until the end of the study.

Safety

Adverse events in 6-17-year-old patients

During the MP, AE rates were comparable in the 6-17-year-old groups (incoBoNT/A: 18.2% of patients with AE[s]; placebo: 15.3%). Rates of SAEs, related AEs, AESIs, and AEs leading to discontinuation were low (table 3). The only AESI was 1 case of dysphagia (mild, related to treatment, resolved). One patient per group had AEs
leading to discontinuation (placebo: pneumonia and epilepsy; incoBoNT/A: nasopharyngitis). No major differences between the groups were seen in the most frequent AEs, mostly respiratory infections.

Of the 148 patients (aged 6-17 years) who received incoBoNT/A during the MP, 145 continued in the OLEX period and 43.4% (63/145 patients) experienced AEs during the OLEX (table 3). Most AEs were mild/moderate; most were respiratory tract infections.

SAEs occurred in 8/145 patients (5.5%) and each individual SAE term was reported in only 1 patient. However, functional gastrointestinal disorder occurred in 2 patients. No SAE was related to treatment and no patient died.

Overall, 8/145 patients (5.5%) had AEs assessed as related to treatment; none were serious. Among the related AEs, only dysphagia was reported in more than 1 patient (4 patients, 2.8%) during the OLEX. Dysphagia was the only AESI reported. All 4 patients with dysphagia had single occurrences of the event only (all non-serious, related, mild/moderate, resolved).

AEs leading to discontinuation were documented for 4/145 patients (2.8%), and in 1 of these cases the events (dysphagia, saliva altered, choking) were assessed as related to treatment. The incidences of AEs, SAEs, and other important events did not increase notably with increasing number of cycles (1st cycle [MP]: 27 patients with AEs [18.2%]; 2nd cycle: 25/145 patients [17.2%]; 3rd: 25/141 patients [17.7%], 4th: 32/131 patients [24.4%]). A post-hoc analysis showed a median time to onset of AEs after the respective injection of several weeks (63 days [range 1-147 days] in 1st cycle, 54 days [range 1-123 days] in 2nd cycle, 65 days [range 5-141 days] in 3rd cycle, 84 days [range 16-126 days] in 4th cycle).

In patients who had received placebo in the MP, the overall incidence of AEs in the OLEX (42.0%; 29/69 patients with AE[s]) was comparable to that in patients who had received incoBoNT/A in the MP. Two patients (2.9%) from the MP placebo group
experienced related AEs during the OLEX. No SAE, AESI, AE leading to discontinuation, or death occurred in this group.

**Adverse events in 2-5-year-old patients**

During the MP, 14.3% of the 2-5-year-olds (5/35 patients) experienced AEs. One patient (2.9%) had AEs related to treatment (administration site conditions). Another patient experienced 2 SAEs (staphylococcal bacteremia, generalized tonic-clonic seizure [leading to discontinuation], both not related). No AESI and no death was reported. The only AE that occurred in more than 1 patient was nasopharyngitis (2 patients).

During the OLEX, AEs were documented for 15/33 patients (45.5%). No related AE, SAE, AESI, AE leading to discontinuation, or death was reported. Most events were respiratory infections. The AE rate varied between the injection cycles (1st cycle [MP]: 14.3%; 2nd cycle: 21.2%; 3rd: 15.2%; 4th: 33.3%).

**Other safety parameters**

Regarding dental/periodontal AEs, oropharyngeal pain was reported for 3 patients (2.1%) and oral herpes and dental caries for 2 patients (1.4%) each, during the OLEX. Among the patients for whom antibody testing was performed, 3 showed positive results at baseline and at study end, but all responded to treatment despite the presence of antibodies against botulinum toxin A. No patient newly developed neutralizing antibodies under therapy.

**Classification of evidence**

This prospective study with a randomized, double-blind, placebo-controlled MP and an OLEX assessed the efficacy and safety of incoBoNT/A (up to 75 U) for reduction of the salivary flow rate and improvement of chronic sialorrhea in children and adolescents. This study provides Class I evidence that injection of incoBoNT/A decreases drooling in children aged 6-17 years with neurological disorders.
Discussion

The SIPEXI study demonstrated that incoBoNT/A was effective and safe for the treatment of sialorrhea in children and adolescents. Management of sialorrhea with incoBoNT/A showed significant and sustained reduction of salivary flow, improving quality-of-life in 6-17-year-old patients. Both co-primary efficacy endpoints were reached, confirming superiority of incoBoNT/A over placebo. The results were robust and consistent for all parameters. The significant decrease in uSFR was accompanied by improved quality-of-life indicators: GICS ratings, mTDS ratings, and DQs. The reduced salivary flow, as seen in the uSFR and DQ results, appeared to be clinically meaningful for the patients, easing sialorrhea's impact on everyday life, as seen in the GICS and mTDS results. The mean change seen in the GICS was +0.9 points already at week 4 for the incoBoNT/A group, with >60% of patients showing a response of at least +1 point ("minimally improved"). In the OLEX, ratings around +2 ("much improved") were reached. As the maximum attainable improvement on the GICS is +3, it can be assumed that changes of +1 and +2 are meaningful. This is corroborated by the mTDS results, which provide a more tangible measure of the treatment's impact on daily life. The mean baseline mTDS ratings for the incoBoNT/A group of 6-17-year-olds were between 7 points ("severe drooling; clothing becomes damp frequently") and 8 points ("profuse drooling; clothing, hands, and objects become wet occasionally") on the 9-point scale. After 4 weeks, the mean mTDS ratings in this group had already decreased to around 6 points ("severe drooling; clothing becomes damp occasionally"), followed by further improvements to around 3 points ("mild drooling; only lips are wet, but frequently") at the end of the OLEX.

Of note, the analyses of GICS response rates (≥+1 point improvement) also showed a response in the placebo group. However, this was consistently lower than in the
incoBoNT/A group. Placebo responses are well known in developmental disabilities\textsuperscript{28} and might be attributed in this study to expectancy effects (positive expectancy by parents/caregivers, physicians’ enthusiasm as the effects of BoNT/A on drooling were already well described in the scientific literature at the time of the study), and to participations effects (raised awareness of health issues and modified behaviors improving health due to study participation). These effects might be even larger in children than in adults.\textsuperscript{29} Furthermore, the fact that a treatment effect was detected in the incoBoNT/A as well as in the placebo group proved efficient blinding. The observed placebo effect decreased and the difference to verum increased over time. A study on a comparable pediatric population treated with glycopyrrolate also showed a placebo response for a global efficacy assessment, which was, however, lower than the response to active treatment.\textsuperscript{30}

The SIPEXI study results were in line with those from the SIAXI study, a similar trial in adults with sialorrhea, which showed good efficacy and safety for incoBoNT/A (75 U and 100 U) compared to placebo, and lasting treatment effects over up to 4 injection cycles.\textsuperscript{10, 11}

Sialorrhea often requires continuous, long-term treatment. Therefore, SIPEXI investigated the effect of 4 consecutive treatments over more than 1 year. A sustained benefit of repeated treatments became apparent over time. Treatment effects became slightly greater with each treatment cycle, indicating a build-up of efficacy. No substantial waning of effect was seen up to 4 months after injection, supporting the notion that up to 3 repeated treatments per year may be sufficient to control sialorrhea.

Comparisons of the SIPEXI results with published literature are limited by differences in study design and endpoints. Furthermore, the published studies of botulinum toxin treatments for pediatric sialorrhea cited here describe the use of onabotulinumtoxinA. The total incoBoNT/A doses employed in SIPEXI (1.3-2.2 U/kg/session, with a
maximum of 75 U for patients with BW $\geq$ 30 kg) were in the medium range of doses reported for onabotulinumtoxinA.

In the literature, higher doses appear to lead to greater improvements in sialorrhea.$^{16}$ In SIPEXI, the decrease in mean uSFR from baseline to week 4 represents a reduction of around 23%. Even higher decreases in salivary flow of almost 50% have been reported with higher doses of onabotulinumtoxinA.$^{16}$ However, higher doses also appear to lead to more safety issues.$^{16, 31-34}$

DQ results in several published studies were comparable to the present trial. In SIPEXI, the DQ for the incoBoNT/A group decreased by 11% to 14% after 1 treatment cycle. This is in line with several smaller studies in children, where similar ranges of DQ improvements were seen after injections with up to 50 U onabotulinumtoxinA.$^{24, 35, 36}$

The SIPEXI results support the concept of a balance between clinically meaningful efficacy and good tolerability and safety by repeated application of medium doses instead of aiming for maximum efficacy with the first injection. The careful accumulation of relevant clinical effects over time may be a valuable treatment scheme, especially for pediatric patients. In SIPEXI, the uSFR only slightly decreased from peak effect at week 4 until the end of cycle visit at week 16. This difference became smaller from cycle to cycle, providing sustained improvements without exceeding the desired level of salivary flow reduction. Some decrease in effect was observed after several months, but clinical experience suggests that this diminishes with increasing number of injections. It has been reported that chronic use of intraglandular botulinum toxin reduced gland sizes.$^{37}$ A sustained effect of incoBoNT/A after multiple injections could be due to possible atrophy of the glands. It may be worth investigating the causes of the sustained effect with detailed imaging or pathological studies.
The safety outcomes of SIPEXI were highly encouraging. IncoBoNT/A (20-75 U/kg per session) was shown to be safe and well-tolerated when administered up to 4 times in approximately 1 year, with 16-week intervals. During the MP, AE rates were comparable between active treatment and placebo. Overall, AE rates were comparably low, also for SAEs and AEs indicative of potential toxin spread, e.g., dysphagia. Over the entire study period, the only types of AEs that accumulated were respiratory infections, which are common in children. This increase was most likely season-related, and the results of active questioning for respiratory AESIs revealed no differences between treatment cycles. In other published studies of botulinum toxin treatment for sialorrhea in children, AEs were often not actively monitored, or the focus was on adverse effects only, so rates of complications varied widely, but most events were mild.\textsuperscript{21, 23, 32, 33, 38}

Although a reduced salivary flow could be expected to cause oral health issues,\textsuperscript{39, 40} studies addressing changes in salivary composition and flow after botulinum toxin injections did not report a negative impact on patients’ oral health.\textsuperscript{25, 41} In line with this, in SIPEXI, only few dental/periodontal AEs occurred and there was no evidence of an increase in such AEs with repeated treatments.

Overall, no new or unexpected safety concerns arose, and the high patient retention rate emphasizes tolerability of the treatments. The mandatory ultrasound guidance of injections likely helped minimize AE rates.\textsuperscript{21}

The safety results confirm the established notion that botulinum toxins have a favorable safety profile.\textsuperscript{42-44} Anticholinergic drugs like glycopyrrolate and scopolamine, while effective, typically have notably more systemic side effects like behavioral changes, constipation, or mouth dryness.\textsuperscript{24, 44-48}

In SIPEXI, the efficacy and safety results for the additional cohort of younger patients aged 2-5 years treated with incoBoNT/A were at least as good as those for the older
patients, although they tended to receive lower doses per kg than the older patients. The efficacy parameters consistently showed notable improvements in sialorrhea over the course of the study and AE rates were low.

The sample size for the group of patients aged 2-5 years was small, no placebo control group was included for ethical reasons, and the uSFR was not assessed because the procedure was not suitable for small children. However, the data indicate that incoBoNT/A can be effective and well-tolerated already in very young patients.

For the group of patients aged 6-17 years, the SIPEXI results provide strong and robust data. The long-term results may be somewhat biased due to the fixed length of the treatment cycles. Apart from this, the study draws its strengths from the large sample size, the multinational setting, the placebo comparison in the MP, the repeated treatments over 1 year, the almost complete data set with few missing values, and the remarkable patient retention. Particular attention was paid to safety, including safety reviews during recruitment and oral health examinations by a dentist. Furthermore, for the safety and accuracy of procedures, ultrasound-guided injections were mandatory and ultrasound training was provided for the study sites.

The findings presented here show that a conservative, BW-dependent dosing approach using 20 U to 75 U incoBoNT/A for repeated treatment of sialorrhea in children can minimize side effects while attaining good efficacy and clinically relevant improvements of sialorrhea. This approach is a relevant option for clinicians deciding on optimal, individual treatment for children with chronic sialorrhea.
## Appendix 1. Authors

| Name                                      | Location                                                                 | Contribution                                                                 |
|-------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| Prof. Dr. Steffen Berweck, MD             | Schön Klinik, Vogtareuth, Germany and Dr. von Hauner Children’s Hospital, Ludwig-Maximilians-University (LMU), Munich, Germany | Involved in:  
- study concept and design,  
- acquisition, analysis and interpretation of study data,  
- critical revision of manuscript for important intellectual content |
| Marcin Bonikowski, MD, PhD                | Mazovian Neuropsychiatry Center, Zagórze n. Warsaw, Poland                                                                       | Involved in:  
- acquisition and interpretation of study data,  
- critical revision of manuscript for important intellectual content |
| Heakyung Kim, MD                          | Pediatric Rehabilitation Medicine at the Department of Rehabilitation & Regenerative Medicine of Columbia University Irving Medical Center/New York Presbyterian Hospital, New York, NY, U.S.A. | Involved in:  
- critical revision of manuscript for important intellectual content |
| Michael Althaus, MD, FFPM                 | Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany                                                                            | Involved in:  
- study concept and design,  
- acquisition, analysis and interpretation of study data,  
- critical revision of manuscript for important intellectual content |
| Birgit Flatau-Baqué                      | Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany                                                                            | Involved in:  
- study concept and design,  
- acquisition, analysis and interpretation of study data,  
- critical revision of manuscript for important intellectual content |
| Daniela Mueller, PhD                      | Kantar Health, Munich, Germany                                                                                                 | Involved in:  
- drafting and critical revision of manuscript for important intellectual content |
| Marta Banach, MD, PhD                     | Jagiellonian University, Krakow, Poland                                                                                         | Involved in:  
- study concept and design,  
- acquisition, analysis and interpretation of study data,  
- critical revision of manuscript for important intellectual content |
References


Figure 1 Disposition of patients for the MP and OLEX of the study, with patient numbers for each treatment arm and phase

Legend:

Multiple reasons for discontinuation were possible.

Abbreviations: MP: main period; OLEX: open-label extension period.
Figure 2 Carers’ GICS mean ratings at the main period visits (active treatment compared to placebo)

Legend:

Results for incoBoNT/A group shown in green, placebo in grey.

Means are LS-means (adjusted) from MMRM analysis. Week 4 (4 weeks after MP injection) was the time point of the primary analysis.

GICS 7-point scale from -3 (very much worse) to +3 (very much improved).

Data based on full analysis set (6-17 years). Error bars show SE.

* p < 0.05, ** p < 0.01, *** p ≤ 0.001.

Abbreviations: GICS: global impression of change scale; LS: least squares; MMRM: mixed model repeated measures; MP: main period; SE: standard error.
Figure 3 Unstimulated salivary flow rate (uSFR, g/min), mean changes from study baseline to all main period and OLEX period visits

Legend:

Each week 4 visit (4 weeks after respective injection) in dark blue; each week 16 visit in light blue. Data based on FAS/SES (6-17 years), subset of patients who received incoBoNT/A throughout the study (no placebo). Error bars show SE. Means are unadjusted.

Abbreviations: FAS: full analysis set; incoBoNT/A: incobotulinumtoxinA; OLEX: open-label extension period; SE: standard error; SES: safety evaluation set; uSFR: unstimulated salivary flow rate; W4/W16: week 4/week 16 visit.
Figure 4 Carers’ GICS mean ratings at all main period and OLEX period visits

Legend:

Each week 4 visit (4 weeks after respective injection) in dark red; each week 16 visit in light red.
GICS 7-point scale from -3 (very much worse) to +3 (very much improved).
Data based on FAS/SES (6-17 years), subset of patients who received incoBoNT/A throughout the study (no placebo). Error bars show SE. Means are unadjusted.
Abbreviations: FAS: full analysis set; GICS: global impression of change scale; incoBoNT/A: incobotulinumtoxinA; OLEX: open-label extension period; SE: standard error; SES: safety evaluation set; W4/W16: week 4/week 16 visit.
## Tables

### Table 1 Patient demographics and baseline disease characteristics

<table>
<thead>
<tr>
<th></th>
<th>Placebo (6-17 years N=72)</th>
<th>IncoBoNT/A (6-17 years N=148)</th>
<th>IncoBoNT/A (2-5 years N=35)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>45 (62.5%)</td>
<td>93 (62.8%)</td>
<td>22 (62.9%)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>27 (37.5%)</td>
<td>55 (37.2%)</td>
<td>13 (37.1%)</td>
</tr>
<tr>
<td>Age [years], mean (SD)</td>
<td>10.3 (3.25)</td>
<td>10.4 (3.17)</td>
<td>3.9 (0.91)</td>
</tr>
<tr>
<td>BMI [kg/m²], mean (SD)</td>
<td>16.4 (3.65)</td>
<td>15.8 (3.25)</td>
<td>15.3 (1.85)</td>
</tr>
<tr>
<td><strong>Baseline disease characteristics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intellectual disability, n (%)</td>
<td>64 (88.9%)</td>
<td>130 (87.8%)</td>
<td>33 (94.3%)</td>
</tr>
<tr>
<td>Primary diagnosis leading to sialorrhea:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cerebral palsy, n (%)</td>
<td>43 (59.7%)</td>
<td>102 (68.9%)</td>
<td>20 (57.1%)</td>
</tr>
<tr>
<td>Traumatic brain injury, n (%)</td>
<td>1 (1.4%)</td>
<td>9 (6.1%)</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>Other, n (%) a</td>
<td>28 (38.9%)</td>
<td>37 (25.0%)</td>
<td>15 (42.9%)</td>
</tr>
<tr>
<td><strong>Baseline assessments, mean (SD)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>uSFR (g/min)</td>
<td>0.60 (0.25)</td>
<td>0.57 (0.25)</td>
<td>n.a. b</td>
</tr>
<tr>
<td>Carers’ mTDS</td>
<td>7.7 (1.2)</td>
<td>7.6 (1.2)</td>
<td>8.0 (1.0)</td>
</tr>
<tr>
<td>Investigators’ mTDS</td>
<td>7.7 (1.2)</td>
<td>7.7 (1.1)</td>
<td>8.0 (1.0)</td>
</tr>
<tr>
<td>DQ (%)</td>
<td>46.81 (25.25)</td>
<td>42.45 (22.32)</td>
<td>45.96 (25.85)</td>
</tr>
<tr>
<td>For cerebral palsy patients (N):</td>
<td>N=43</td>
<td>N=102</td>
<td>N=20</td>
</tr>
<tr>
<td>baseline GMFCS E&amp;R levels, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Level I</td>
<td>3 (7.0)</td>
<td>5 (4.9)</td>
<td>1 (5.0)</td>
</tr>
<tr>
<td>Level II</td>
<td>11 (25.6)</td>
<td>35 (34.3)</td>
<td>6 (30.0)</td>
</tr>
<tr>
<td>Level III</td>
<td>11 (25.6)</td>
<td>11 (10.8)</td>
<td>3 (15.0)</td>
</tr>
<tr>
<td>Level IV</td>
<td>11 (25.6)</td>
<td>20 (19.6)</td>
<td>1 (5.0)</td>
</tr>
<tr>
<td>Level V</td>
<td>Placebo (6-17 years, N=72)</td>
<td>IncoBoNT/A (6-17 years, N=148)</td>
<td>IncoBoNT/A (2-5 years, N=35)</td>
</tr>
<tr>
<td>---------</td>
<td>---------------------------</td>
<td>--------------------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td></td>
<td>7 (16.3)</td>
<td>31 (30.4)</td>
<td>9 (45.0)</td>
</tr>
</tbody>
</table>

*a “Other diagnoses” comprised a broad range of neurological conditions, as documented by the treating physicians.

*b uSFR not measured for 2-5-year-olds because method was considered inappropriate for this group.

*c Assessment missing for 1 patient.

*d GMFCS E&R levels: I = walks without limitations, II = walks with limitations, III = walks using a hand-held mobility device, IV = self-mobility with limitations; may use powered mobile, V = transported in a manual wheelchair.

Abbreviations: BMI: body mass index; DQ: drooling quotient; GMFCS E&R: Gross Motor Function Classification System (expanded and revised); incoBoNT/A: incobotulinumtoxinA; mTDS: modified Teacher’s drooling scale; n.a.: not available; uSFR: unstimulated salivary flow rate.
<table>
<thead>
<tr>
<th></th>
<th>Placebo (n=72)</th>
<th>IncoBoNT/A (n=148)</th>
<th>Difference (MMRM)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LS-mean (SE)</td>
<td>LS-mean (SE)</td>
<td>LS-mean (SE)</td>
</tr>
<tr>
<td></td>
<td>95% CI</td>
<td>95% CI</td>
<td>95% CI</td>
</tr>
<tr>
<td>Week 4</td>
<td>-0.07 (0.015)</td>
<td>-0.14 (0.012)</td>
<td>-0.06 (0.019)</td>
</tr>
<tr>
<td></td>
<td>-0.10; -0.16</td>
<td>-0.11</td>
<td>-0.10; -0.03</td>
</tr>
<tr>
<td>Week 8</td>
<td>-0.07 (0.015)</td>
<td>-0.16 (0.012)</td>
<td>-0.09 (0.019)</td>
</tr>
<tr>
<td></td>
<td>-0.10; -0.18</td>
<td>-0.13</td>
<td>-0.12</td>
</tr>
<tr>
<td>Week 12</td>
<td>-0.06 (0.016)</td>
<td>-0.16 (0.013)</td>
<td>-0.10 (0.021)</td>
</tr>
<tr>
<td></td>
<td>-0.10; -0.19</td>
<td>-0.14</td>
<td>-0.14</td>
</tr>
<tr>
<td>Week 16</td>
<td>-0.08 (0.015)</td>
<td>-0.15 (0.013)</td>
<td>-0.07 (0.019)</td>
</tr>
<tr>
<td></td>
<td>-0.11; -0.18</td>
<td>-0.12</td>
<td>-0.11</td>
</tr>
</tbody>
</table>

Means are LS-means (adjusted) from MMRM analysis.
Week 4 (4 weeks after MP injection) was the time point of the primary analysis.
Data based on full analysis set (6-17 years).
Abbreviations: incoBoNT/A: incobotulinumtoxinA; LS: least squares; MMRM: mixed model repeated measures; SE: standard error; uSFR: unstimulated salivary flow rate.
Table 3 Summary of all adverse events in main period and in OLEX period (6-17-year-olds)

<table>
<thead>
<tr>
<th>Number of patients (%) with</th>
<th>Placebo (n=72)</th>
<th>IncoBoNT/A (n=148)</th>
<th>IncoBoNT/A (n=145)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE(s)</td>
<td>11 (15.3)</td>
<td>27 (18.2)</td>
<td>63 (43.4)</td>
</tr>
<tr>
<td>AE(s) related to treatment</td>
<td>0 (0.0)</td>
<td>2 (1.4)</td>
<td>8 (5.5)</td>
</tr>
<tr>
<td>AESI(s)</td>
<td>0 (0.0)</td>
<td>1 (0.7)</td>
<td>4 (2.8)</td>
</tr>
<tr>
<td>AESI(s) related to treatment</td>
<td>0 (0.0)</td>
<td>1 (0.7)</td>
<td>4 (2.8)</td>
</tr>
<tr>
<td>SAE(s)</td>
<td>1 (1.4)</td>
<td>0 (0.0)</td>
<td>8 (5.5)</td>
</tr>
<tr>
<td>SAE(s) related to treatment</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>AE(s) leading to discontinuation</td>
<td>1 (1.4)</td>
<td>1 (0.7)</td>
<td>4 (2.8)</td>
</tr>
<tr>
<td>AE(s) leading to discontinuation related to treatment</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>1 (0.7)</td>
</tr>
<tr>
<td>Fatal AE(s)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
</tr>
</tbody>
</table>

*MedDRA preferred terms of the SAEs in these patients: functional gastrointestinal disorder (2 patients) gastrointestinal hemorrhage, haematemesis, gastroenteritis rotavirus, influenza, pneumonia, pneumonia bacterial, respiratory tract infection, foreign body in gastrointestinal tract, joint dislocation, anaemia, limb deformity, gastric operation.

Data based on safety evaluation set (6-17 years). Cumulative OLEX data from safety evaluation set (6-17 years) of patients who had received incoBoNT/A already in the MP.

AEs during MP were defined as treatment-emergent with onset or worsening at or after first injection of incoBoNT/A or placebo up to and before first injection of OLEX or, in case of discontinuation before OLEX, up to and including 16 weeks after first injection or last study visit, whichever was later.

Abbreviations: AE: adverse event; AESI: adverse event of special interest; incoBoNT/A: incobotulinumtoxinA; MP: main period; OLEX: open-label extension period; SAE: serious adverse event.